Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

UCB and IBM to harness big data for personalised epilepsy care

Joint project could pave the way for therapy area use of IBM's Watson

UCB and IBM are collaborating on a project that could eventually see 'cognitive computing' capabilities, such as the IT giant's own supercomputer Watson, used in epilepsy care.

Still in its early stages, the partners are working on using big data and analytics to help healthcare providers deliver more personalised care for epilepsy patients.

They want to do this by producing the healthcare industry's most comprehensive body of information on epilepsy, combining both patient data and scientific literature.

An interactive system will then be created to translate this big data into predictive analytics that healthcare professionals can consult, at the point of care, to inform their treatment decisions.

The system would determine the probability that specific approaches to care will be successful.

Robert Merkel, global healthcare and life sciences industry leader, IBM Global Business Services: “Technologies, like analytics and cognitive computing applied to big data, are revolutionising the way we deliver and receive care.

“IBM is dedicating innovation and expertise to help UCB prove the predictive value of this technology that would arm physicians with information that will help them identify the best possible treatment options and improve quality of care for patients suffering from epilepsy.”

The approach is also one UCB and IBM say will help lay the foundation for using cognitive computing, natural language processing, and machine learning capabilities to raise the standard of care in epilepsy.

UCB's chief medical officer Dr Iris Löw-Friedrich said: “UCB focuses on the creation of innovative networks because we recognise that delivering best-in-class solutions to patients requires collaboration with a diverse group of internal and external experts.

“We have partnered with IBM to explore this concept of streamlining large amounts of data into actionable approaches to epilepsy care.”

If the project, which has just completed its initial phase, is a success it could open up a huge market for IBM and Watson – which is already being tested as a clinical decision support system by two US medical practices.

17th May 2013

From: Research, Healthcare

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....

Infographics